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Abstract
Background: Heat shock protein 90 (HSP90) is a molecular chaperone that is considered a new target for the
treatment of cancer. Increasing data reveal an extracellular chaperoning activity for HSP90. Here we investigate the
interaction of the secreted isoforms of HSP90 with matrix metalloproteinases (MMP) MMP2 and MMP9. Moreover
we examine the role of a monoclonal antibody (mAb) against HSP90, mAb 4C5, regarding these interactions and
its value as a potential inhibitor of human breast cancer cell invasion and metastasis.
Results: Our results showed that both HSP90a and HSP90b are secreted by MDAMB453 human breast cancer cells
and interact with MMP2 and MMP9. MAb 4C5, while not affecting the secretion of inactive MMPs, inhibits their
activation by disrupting their interaction extracellularly with both isoforms of HSP90. The in vivo studies revealed
that mAb 4C5 significantly inhibits the metastatic deposit formation of MDAMB453 cells into the lungs of SCID
mice.
Conclusion: Both isoforms of HSP90 are secreted by MDAMB453 cells and interact with MMP2 and MMP9. MAb
4C5 prevents MMP2 and MMP9 activation, by disrupting their interaction with HSP90. Finally mAb 4C5 significantly
inhibits the metastatic deposit formation of MDAMB453 cells, by preventing their extravasation and infiltration in
the lung tissue and therefore it could be used as a potential therapeutic agent for cancer metastasis.
Background
The dissemination of tumor cells from their primary site
of growth to distant organs is the major cause of mor-
bidity and death among cancer patients [1,2]. Thus,
inhibition of invasion and metastasis of cancer cells is of
great importance in the treatment of cancer. Cancer cell
invasion and metastasis is considered to be a complex,
multi-step process, during which malignant cells detach
from their point of origin, migrate and invade surround-
ing tissues, enter the vasculature, circulate and reach
secondary sites, extravasate and establish metastatic foci
[3,4].
One well-characterized property of invasive tumors is
their ability to accelerate the degradation of the
extracellular matrix, by matrix metalloproteinases
(MMPs) [5].This degradation provides access to the vas-
culature and lymphatic system, allowing tumor dissemi-
nation. MMPs have increased expression and activation
in almost all human cancers[6]. More specifically,
MMP2 and MMP9 are of particular interest because in
addition to gelatin they degrade type IV collagen, the
basic component of the basement membrane, which is
the main barrier separating in situ and invasive carci-
noma [7,8].
The heat shock protein 90 (HSP90) is a molecular
chaperone which exists in mammalian cells in two iso-
forms that share 86% aminoacid conservation (HSP90a
and HSP90b). It is one of the most abundant cytoplas-
mic proteins in unstressed cells, where it performs
housekeeping functions, controlling the activity, intracel-
lular disposition and proteolytic turnover of a variety of
proteins. Over the past years there has been increasing
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molecules intracellularly, that are involved in the devel-
opment and/or survival of cancer cells [9-11], allowing
mutant proteins to retain or gain function, while permit-
ting cancer cells to tolerate the imbalanced signaling
that such oncoproteins create. Recently, we and others
have identified a pool of HSP90 at the cell surface,
where it was shown to be involved in cancer cell inva-
sion [12]. Additionally, we have reported results showing
that a monoclonal antibody (mAb) recognizing both the
a and the b isoforms of HSP90, mAb 4C5, inhibits mel-
anoma cell invasion and metastasis by binding selec-
tively to the surface pool of HSP90 [13]. Finally, we
have presented data indicating that surface HSP90 inter-
acts specifically with the extracellular domain of HER-2
and that this interaction which is necessary for the
receptor’s activation leading to breast cancer cell inva-
sion, is disrupted by mAb 4C5 [14].
Taking all the above into consideration together with
previous data showing that HSP90a is secreted from
fibrosarcoma cells and promotes their invasive capacity
through association with MMP2 [15], in the present
work we sought to investigate the secretion of both the
a and the b isoforms of HSP90 in the conditioned med-
ium of MDAMB453 human breast cancer cells and their
possible interaction with MMP2 and/or MMP9. Further-
more and after taking into account our previously men-
tioned recent data showing that mAb 4C5 inhibits
MDAMB453 human breast cancer cell invasion in vitro
by disrupting the association of cell surface HSP90 with
HER-2,[14] in this work we examined: a) the effect of
mAb 4C5 on MMP2 and MMP9 secretion and activa-
tion b) the ability of this antibody to disrupt the interac-
tion of extracellular HSP90 with MMP2 and/or MMP9
and c) the capacity of mAb 4C5 to inhibit in vivo,t h e
formation of metastatic deposits of MDAMB453 cells in
the lungs of SCID mice.
Results
Both the a and b isoforms of HSP90 are secreted by
MDAMB453 breast cancer cells and interact with MMP2
and MMP9
In order to investigate the secretion of the a and b iso-
forms of HSP90 by MDAMB453 cells, cell lysates and
concentrated supernatants derived from the culture of
these cells were analyzed by Western blotting using
mAb 4C5 which recognizes both isoforms of HSP90[16],
and the commercially available anti-HSP90 a and
anti-HSP90 b antibodies. As shown in Figure 1A, both
the a and the b isoforms of HSP90 are secreted by
MDAMB453 cells. The absence of beta actin in the
supernatant fraction (Figure.1A) demonstrates that
there is no contamination of the culture supernatants
with the intracellular components of cells during the
experimental procedure. At this point it is important to
note that beta actin was never detected in any of the
concentrated supernatants used in the experiments
described hereafter (data not shown).
An important characteristic of invasive tumors is their
capacity to accelerate the degradation of extracellular
matrix by MMPs [5]. MMPs are secreted as inactive
pro-enzymes and are activated extracellularly by proteo-
lysis [17]. We thus next examined the possible interac-
tion of the secreted pool of HSP90 with MMP2 and
MMP9. After confirming the presence of both pro-
MMP2 and pro-MMP9 as well as their activated forms
in the culture medium of MDAMB453 cells (Figure.1B),
we showed by immunoprecipitation experiments in the
culture supernatant using anti-MMP2 and anti-MMP9
antibodies followed by Western blot analysis with anti-
bodies against the a and b isoforms of HSP90, that
indeed both isoforms of HSP90 interact with the metal-
loproteinases examined (Figure.1B). In order to further
clarify the interaction of extracellular HSP90 with the
MMPs studied, reverse co-immunopercipitation experi-
ments were performed. Our results showed that both
the a and the b isoforms of HSP90 interact with the
inactive pro-MMP2 and pro-MMP9 (Figure.1C). Interac-
tion with the mature forms of the corresponding metal-
loproteinases was also detected (Figure.1C).
MAb4C5 prevents MMP2 and MMP9 activation and
disrupts their interaction with both the a and the b
isoform of extracellular HSP90
Based on our observation that presence of both the
inactive and mature forms of MMP2 and MMP9 were
detected in the concentrated supernatants derived from
MDAMB453 cell cultures, we next examined the effect
of mAb 4C5, the function blocking anti-HSP90 anti-
body, on the secretion and activation of MMP2 and
MMP9. Analysis of concentrated supernatants derived
from MDAMB453 cells, with zymography, showed that
when 200 μg/ml of mAb 4C5 were included in the cul-
ture medium, presence of the inactive pro-enzymes was
not affected, while detection of the activated forms of
both MMPs was not obtained (Figure.2A). These results
were confirmed using antibodies against the metallopro-
teinases, and western blot analysis (Figure.2B). At this
point it is important to note that addition of mAb 4C5
in the culture medium did not affect secretion of
HSP90a or HSP90b (data not shown).
Consequently and taking into account the previously
demonstrated interactions of both isoforms of HSP90
with MMP2 and MMP9, we explored the role of mAb
4C5 in relation to these interactions, using co-immuno-
precipitation experiments. To this purpose, concentrated
conditioned media derived either from control or mAb
4C5 treated cultures were immunoprecipitated with
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tern blot analysis with antibodies against the a and the
b isoforms of HSP90. As shown in Figure 2C, co-immu-
noprecipitation of both isoforms of HSP90 with the
inactive forms of MMP2 and MMP9 was inhibited in
the media derived from the cells cultured in the pre-
sence of mAb 4C5, when compared with control cul-
tures. This result indicates that mAb 4C5 disrupts
extracellularly the interaction of both pro-MMP2 and
pro-MMP9 with the two isoforms of HSP90.
MAb4C5 inhibits the metastatic deposition of MDAMB453
breast cancer cells into the lungs of SCID mice
On the basis of previously reported studies using the
MDAMB453 cell line [14] and showing that mAb 4C5
inhibits the invasion of these cells in vitro,w en e x t
sought to investigate the in vivo effect of mAb 4C5 on
the metastatic behavior of this breast cancer cell line.
Thus, we injected MDAMB453 cells labeled with the
fluorescent dye DiI intravenously in SCID mice, either
i nt h ep r e s e n c eo ri nt h ea b s e n c eo f1 0 0μg/ml of mAb
4C5. Twenty four hours after the injection, mice were
euthanized and the metastatic deposits of MDAMB453
cells were traced and evaluated in the lungs of both the
control and the mAb 4C5 treated groups. At the macro-
scopic level an important number of metastatic cell
deposits (arrow in Figure.3A) was observed in control
animals as compared to mAb 4C5 treated mice. This
was confirmed microscopically where a very important
decrease in the deposition of cancer cells was detected
in the mAb 4C5 treated mice (arrows in Figure.3B).
Quantification of the metastatic deposit formation
revealed a 86.67% inhibition in the mAb 4C5 treated
mice when compared with control mice (Figure.3C). In
order to further visualize the deposition of MDAMB453
cells in the lung tissue, we performed a 3D reconstitu-
tion of a cryosection derived from a control animal
where the infiltration of metastatic deposits of
Figure 1 Both the a and the b isoforms of HSP90 are secreted by MDAMB453 cells and interact with MMP2 and MMP9
metalloproteinases. (A) Cell lysates were immunoblotted with mAb 4C5 recognizing both isoforms of HSP90 and serving as positive control.
Concentrated supernatants derived from the cell cultures as described in Methods, were analyzed by Western blot using anti HSP90 a and anti
HSP90 b antibodies and mAb 4C5. Anti beta actin antibody was used in both fractions. Secretion of the two isoforms of HSP90 was detected in
the supernatant derived from MDAMB453 cells. The absence of beta actin in the supernatant demonstrates that there is no contamination of
this fraction with the intracellular components of cells during the experimental procedure. (B) Western blot analysis of concentrated supernatants
derived from MDAMB453 cell cultures, using anti-MMP2 and anti-MMP9 antibodies showed that both the pro-MMP2 and pro-MMP9 as well as
their activated forms are present in the culture medium. Proteins derived from the culture supernatant were immunoprecipitated with anti-
MMP2 and anti-MMP9 and bound proteins were analyzed by Western blot with anti-HSP90a and anti-HSP90b antibodies. Both isoforms of
HSP90 interact with the two metalloproteinases. Irrelevant IgGs and anti-MMP2 or anti-MMP9 antibodies were used as negative and positive
controls respectively. (C) Proteins derived from the MDAMB453 cell culture supernatant were immunoprecipitated with anti-HSP90a and anti-
HSP90b antibodies and immunoprecipitants were analyzed by Western blot using the anti-MMP2 and anti-MMP9 antibodies. Irrelevant IgGs and
anti-HSP90 a or anti-HSP90 b antibodies were used as negative and positive controls respectively. The reverse immunoprecipitation experiment
showed that both isoforms of HSP90 interact with pro-MMP2 and pro-MMP9 and to a lesser extent with the activated forms of the two
metalloproteinases. IP immunoprecipitation, WB Western blot.
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strated (arrow in Figure.3D). It is of interest to note that
in the mAb 4C5 treated mice, MDAMB453 cells were
often observed stagnating on the inner surface of large
pulmonary blood vessels whereas no such images could
be detected in the control animals (arrows in Figure.3E).
Quantification of this occurrence revealed that in
58.76% of the pulmonary vessels visualized in the,
mAb4C5 treated animals, MDAMB453 cells were
observed stagnating on the inner surface of the vessels.
In contrast, only 15.4% of the vessels observed in the
control animals showed intravascular retention of the
cancer cells. (Figure 3F).
Discussion
Our present findings demonstrate that both the a and
the b isoforms of HSP90 are secreted by cultured
MDAMB453 human breast cancer cells and interact
with matrix metalloproteinases, MMP2 and MMP9.
Additionally, we show that a monoclonal antibody
against HSP90, mAb 4C5, prevents maturation of the
two metalloproteinases in vitro and inhibits metastatic
deposition of breast cancer cells in vivo.
We have previously reported the presence of HSP90a
and HSP90b on the cell surface of MDAMB453 breast
cancer cells [14]. Here we further examined the extra-
cellular localization of HSP90. More specifically, we
demonstrated the secretion of both HSP90a and
HSP90b in the culture medium of MDAMB453 cells
using antibodies specific for the two isoforms. At this
point it is important to note that specificity of the anti-
HSP90b antibody was further confirmed since, Western
blot analysis of human recombinant HSP90a using this
antibody gave negative results (see additional files 1 and
2). Our findings, for the first time to our knowledge,
reveal secretion of HSP90b by breast cancer cells and
are only partly in agreement with existing knowledge.
Indeed, previous studies have reported secretion only of
HSP90a from various cell types including HT 1080
fibrosarcoma cells [15], human dermal fibroblasts under
hypoxia conditions[18] and transforming growth factor
alpha stimulated human keratinocytes [19]
Controlled degradation of the extracellular matrix is
essential for the invasion and metastasis of malignant
tumors. In this context matrix metalloproteinases and in
particular MMP2 and MMP9 are of crucial significance
Figure 2 MAb4C5 prevents MMP2 and MMP9 activation and disrupts their interaction with both the a and the b isoform of
extracellular HSP90. (A) Metalloproteinases derived from the concentrated supernatants of control and mAb 4C5 treated cultures of
MDAMB453 cells were isolated and analyzed by zymography, as described in Methods. Proteolysis was detected as a white zone in a dark field.
Metalloproteinases previously isolated as described in Methods were used as markers. Activated MMP2 and MMP9 are absent in the mAb 4C5
treated cultures. (B) Proteins derived from the concentrated supernatants of control and mAb 4C5 treated cultures of MDAMB453 cells, prepared
as described in Methods, were analyzed by Western blot using anti-MMP2 and anti-MMP9 antibodies. Presence of mAb 4C5 in the culture
medium inhibits activation of both metalloproteinases. (C) Proteins from the above described supernatants were immunoprecipitated with anti-
MMP2 and anti-MMP9 antibodies and bound proteins were analyzed by Western blot with anti-HSP90a and anti-HSP90b antibodies. MAb 4C5
disrupts the association of both isoforms of HSP90 with the two metalloproteinases, since anti-MMP2 and anti-MMP9 antibodies did not co-
immunoprecipitate any detectable levels of HSP90 in the mAb 4C5 treated cultures, when compared with controls. Western blot analysis of the
MMP2 and MMP9 immunoprecipitants, using the corresponding antibodies was performed as positive controls and irrelevant IgGs were used as
negative controls. IP immunoprecipitation, WB Western blot.
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labeled with the fluorescent dye DiI and injected into SCID mice, in the presence either of 100 μg/ml of mAb 4C5 or of an irrelevant antibody
(control), as described in Methods. Evaluation of metastatic deposits was performed several hours later. (A) Macroscopic level: An important
number of metastatic deposits (arrow) was observed in control animals as compared to mAb 4C5 treated mice. (B) Microscopic level:
Representative cryosections of the lungs of control and mAb 4C5 treated mice. The arrows show MDAMB453 cells stained with DiI present in
the lung tissue. A significant decrease in the deposition of cancer cells was observed in the mAb4C5 treated mice. (C) Quantitative effect of
mAb 4C5 on the metastatic deposition of MDAMB453 cells into the lungs showed an 86.67% inhibition of the metastatic deposition in the mAb
4C5 treated mice when compared to the control animals. (D) A 3D reconstitution of a cryosection from a control animal: The arrow
demonstrates infiltration of metastatic deposits in the lung tissue. (E) MDAMB453 cells restrained in the inner surface of large pulmonary vessels
derived from mAb 4C5 treated mice. On the contrary, in the lungs from control mice MDAMB453 cells could rarely be detected stagnating in
the inner surface of the pulmonary vessels. However, cancer cells were clearly observed dispersed in the lung tissue. Arrows indicate the
pulmonary vessels. (F) Quantitative effect of mAb 4C5 on the retention of MDAMB453 cells in the pulmonary vessels. A 15.4% of the vessels
visualized in the control animals showed intravascular cancer cell retention. In contrast in the mAb 4C5 treated mice, cancer cells were observed
stagnating in the inner surface of 58.76% of the calculated vessels (p < 0.01 Bar, 40 μm).
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increasing experimental evidence indicates involvement
of both enzymes at multiple steps of the metastatic pro-
cess[21] It is important to note that these metalloprotei-
nases are secreted as inactive pro- enzymes and acquire
their active form extracellularly [3,22]. Taking these into
account together with accumulating data demonstrating
extracellular activity of HSP90 [12], we next examined
the possible interaction of this molecule with the two
metalloproteinases using co-immunoprecipitation
experiments. Our results showed that both the a and
the b isoforms of HSP90 interact with the secreted,
inactive forms of MMP2 and MMP9. Interestingly,
reverse co-immunoprecipitation experiments revealed
that HSP90 also interacts, with the extracellularly acti-
vated forms of the two MMPs, The above observations
indicate that HSP90 participates in the activation of
MMP2 and MMP9. Moreover, they suggest a second
level of chaperoning for this molecule associated with
the mature forms of the metalloproteinases examined.
Our findings are in accordance with previously reported
data showing association of the secreted pool of
HSP90a with MMP2 [15,23]. Moreover they provide
new evidence for a further increase in the number of
clients of this chaperone molecule by adding MMP9 to
the list of its extracellular substrates.
We have previously demonstrated that mAb 4C5 inhi-
bits the invasive capacity of MDAMB453 breast cancer
cells by disrupting the interaction of cell surface HSP90
with the extracellular domain of HER-2, a member of
the ErbB family of epidermal growth factor receptors
[14]. Taking this into account together with the above
mentioned findings we next investigated whether mAb
4C5 independently of its effect on HER2 has also an
effect on the secretion and activation of MMP2 and
MMP9. Our results showed that when the cell-
impermeable mAb 4C5 [14] is added to the culture
medium of MDAMB453 cells, secretion of pro-MMP2
and pro-MMP9 is not affected; however and as shown
by zymography and western blot analysis, the activation
of these metalloproteinases is dramatically inhibited as
compared to controls where mAb 4C5 is not included
in the culture medium. Moreover, co-immunoprecipita-
tion experiments performed as described in Methods,
revealed that mAb 4C5 effectively disrupts the interac-
tion of HSP90 with MMP2 and MMP9 respectively. Our
present data indicate that mAb 4C5 while not affecting
secretion of the inactive forms of MMP2 and MMP9,
prevents their maturation most probably by disrupting
their interaction with the extracellular pool of HSP90.
Similar to our results have been previously reported by
Eustace et al [15] who have shown that inhibition of
extracellular HSP90a decreases activation of MMP2.
At this point it should be noted that preliminary
experiments performed using the MDAMB231 breast
cancer cells which lack the HER2 receptor, indicate not
only that these cells too secrete both isoforms of HSP90
but also that MMP2 and MMP9 activation by extracel-
lular HSP90 may be independent of the HER2/HSP90
interaction previously reported [14], since in this system
as well mAb 4C5 prevented activation of these metallo-
proteinases (unpublished data). Nevertheless our overall
observations do not exclude the possibility that in com-
bination with HSP90 additional molecules, such as other
HSPs, HSP90 co-chaperones etc may be necessary for
the activation of the MMPs studied in this work. This
however, needs further investigation.
We have previously demonstrated that mAb 4C5 sig-
nificantly inhibits melanoma metastasis in C57BL/6 mice
inoculated with B16 F10 melanoma cells, [13]. supporting
accumulating data showing that antibodies or other small
molecules that inhibit HSP90 can be used as anti-cancer
agents [24] This prompted us to explore the anti-meta-
static activity of mAb 4C5 with respect to MDAMB453
breast cancer cells. In line with the recently reported
in vitro r e s u l t s[ 1 4 ] ,i nt h i sw o r kw es h o w e dt h a tm A b
4C5 strongly inhibits the metastatic depositions of
MDAMB453 cells into the lungs of SCID mice. More
specifically an 86.67% inhibition of metastatic depositions
of MDAMB453 cells was observed in the mAb 4C5 trea-
ted mice as compared with control animals. It is interest-
ing to note that in the experimental group of mice that
received mAb 4C5, MDAMB453 cells were often
observed stagnating on the inner surface of large pul-
monary vessels, whereas such a phenomenon was very
rarely detected in the control mice. Quantification of this
occurrence confirmed a statistically significant difference
(p < 0,001) between the two experimental groups. This
remarkable observation together with the above men-
tioned data, tempts us to reason that mAb 4C5 exerts its
activity by disrupting the interaction of extracellular
HSP90 with MMP2 and MMP9 and thus preventing acti-
vation of these matrix metalloproteinases which, as is
well documented [7,8], is necessary for the degradation
of type IV collagen, a major constituent of the basement
membrane associated with the pulmonary blood vessel.
As a consequence, tumor cells remain limited to the
inner surface of the vessel and their infiltration into the
lung tissue is impaired. Regulation of MMP activation
has been previously correlated with cancer cell extravasa-
tion. In particular Cruz-Munoz et al have reported that
TIMP-3 decreases MMP2 activation which in turn limits
tumor cell extravasation and subsequent colonization of
the lung[25].
Conclusions
Our present findings combined with recently reported
data [13,14], reinforce and further extend the idea that
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forms of HSP90, at least in relation to cancer cell inva-
sion and metastasis, is exerted at multiple levels such as
activation of growth factor receptor as previously
reported[14] and MMP2 and MMP9 activation. Our
results additionally suggest that extracellular HSP90 may
also chaperone the activity of the mature metalloprotei-
nases with their corresponding substrates. However, elu-
cidation of the precise molecular mechanisms
underlying these interactions needs further investigation.
Finally, our present work further demonstrates the anti-
metastatic capacity of mAb 4C5, showing that it inhibits
not only melanoma metastasis [13] but also the forma-
tion of metastatic breast cancer cell deposits by prevent-
ing extravasation of tumor cells and their invasion in
the lung tissue.
Methods
Reagents
MAb4C5 was produced and characterized, as previously
reported [26]. In the present study, mAb4C5 was used
as concentrated serum free supernatant dialyzed in sal-
ine buffer in all experiments performed. Polyclonal anti-
bodies specific for the a and the b isoforms of HSP90
were obtained from Chemicon. International, USA. At
this point it should be noted that according to the man-
ufacturer, the anti-HSP90b antibody shows no reactivity
with HSP90a and the anti-HSP90a antibody reacts
weakly with HSP90b. Polyclonal antibody recognizing
both the inactivated pro-enzyme and the activated form
of human MMP2 was obtained from Chemicon. Inter-
national, USA. Polyclonal antibody recognizing both the
inactivated pro-enzyme and the activated form of
human MMP9 was obtained from Santa Cruz Biotech-
nology INC. Monoclonal antibody against human beta
actin was obtained from Santa Cruz Biotechnology INC
Polyclonal biotinylated antibodies against anti-rabbit and
anti mouse immunoglobulins were obtained from Dako
Cytomation Denmark A/S. Human recombinant
HSP90a was a generous gift from Dr C. Prodromou,
Institute of Cancer Research. Gelatin-agarose beads,
used for the preclearing of the supernatants, as well as
protein G and protein A-sepharose beads, used for the
co-immunopercipitation experiments, were obtained
from Sigma. Dulbecco’s modified Eagles medium
(DME), fetal bovine serum (FBS), RPMI, were obtained
from Gibco, INC, USA.
Cell cultures
The MDAMB453 human breast cancer cell line was
kindly provided by Dr A.Mamalaki from the Hellenic
Pasteur Institute, Athens, Greece. The cells were seeded
at a density of 2×10
6 cells per cm
2 on plastic dishes as
monolayers in RPMI media containing 10% FBS and
supplemented with the antibiotic garamycin, (10 mg/ml)
in a 5% CO2 humidified atmosphere at 37°C. When cells
reached confluence, the initial medium was replaced by
R P M Iw i t h o u tF B Sa n dt h ec e l l sw e r el e f tf o r2 4h o u r s
in starvation conditions. Subsequently they were
exposed to 200 μg / m lo fm A b4 C 5f o r2 4h .C o n t r o l
cultures were grown for 24 h either in RPMI medium
alone or in culture medium containing 200 μg/ml of an
irrelevant IgG2a monoclonal antibody named BM88
[27].
Preparation of cell lysates and concentrated supernatants
At the termination of the cultures, cells were immedi-
ately washed twice with ice-cold PBS and lysed in 50 μl
lysis buffer (137 mM NaCl, 20 mM Tris/HCl pH 7.4,
50 mM HEPES, 5 mM EDTA, 1 mM DTT, 1 %Triton,
10 %Glycerol, 200 mM Na3VO4, 0.5 mM PMSF, 5 μg/ml
aprotinin, 5 μg/ml pepstatin and 50 μg/ml leupeptin).
Protein lysates were quantified and equal amounts
of total protein were subjected to SDS-PAGE and Wes-
tern blot. Concentrated supernatants derived from
MDAMB453 cells, cultured as described above, were pre-
pared as follows: An initial volume of 20 ml of culture
supernatant was collected from each experimental case
(control and mAb 4C5 treated cultures). At this point it
is important to underline that the supernatants were
derived from the same number of cultured cells, for all
experimental cases. Subsequently 100 fold concentration
was performed using ultra centrifugal filter devices
(10000 MWCO) obtained from Millipore TM. The con-
centrated supernatants were used for all the experimental
procedures concerning immunoprecipitations and Wes-
tern blots. Equal volumes of the concentrated superna-
tants were subjected to SDS-PAGE on 12% acrylamide in
order to obtain the best separating conditions for the
proteins of interest [28]. The analyzed proteins were
transferred to nitrocellulose membranes. For Western
blots, membranes were incubated for 40 min at room
temperature with non-fat dry milk (5%) in TBS and were
then incubated with specific primary antibodies overnight
at 4°C. The membranes were washed with 0.3% BSA in
TBS and incubated with horseradish peroxidase-labeled
secondary antibodies for 2 h at room temperature. After
washing with TBS, the bound antibody complex was
detected using an ECL chemiluminescence reagent
(Amersham) and XOMAT- AR film (Kodak, Pittsburgh,
PA, USA) as described by the manufacturers.
Co-immunoprecipitation
Co-immunoprecipitation was performed as previously
described [29]. In brief, equal amounts of cellular lysates
and equal volumes of the concentrated supernatants
from control and mAb 4C5 treated cultures of
MDAMB453 cells were incubated with antibodies
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incubated for 2 h at room temperature with protein
G-Sepharose or protein A-Sepharose (for the mAb 4C5
treated cultures) and washed 3 times with lysis buffer.
At this point it should be noted that mAb 4C5 does not
bind to protein A Sepharose (unpublished observations)
thus it’s presence did not interfere with the immuno-
precipitation process. Bound proteins were analyzed by
gel electrophoresis and Western blot as described above.
Isolation of metalloproteinases
Isolation of the MMPs from the other proteins present
in the concentrated supernatants was performed as pre-
viously described[30]. Briefly gelatin-Agarose beads were
used in order to form two columns. The concentrated
supernatants of the control and mAb 4C5 treated cul-
tures were loaded on the two columns and washed with
an equilibration buffer containing 0.05Μ Tris-HCl
pH:7,5/0.5 M NaCl, and 0.1% Triton X-100. Gelatine
bound MMPs were eluted with equilibration buffer
containing 1 M NaCl and 5% (v/v) dimethyl sulphoxide.
Zymographs
Equal volumes of isolated MMPs derived from control
and mAb 4C5 treated cultures of MDAMB453 cells,
were denatured and analyzed by gel electrophoresis in a
10% SDS-polyacrylamide gel containing 0.1% (w/v) gela-
tin. The gel was incubated at room temperature for 2 h
in the presence of 2.5% Triton x-100 and subsequently
at 37°C over night in a buffer containing 10 mM CaCl2,
0 . 1 5MN a C l ,a n d5 0m MT r i s( p H7 . 5 ) .T h eg e lw a s
then stained for protein with 0.5% (w/v) Coomassie and
photographed on a light box. Proteolysis was detected as
a white zone in a dark field. MMPs (proenzymes and
active forms) isolated as previously described [30] from
extracts of interface tissue from loose hip arthroplasty
endoprostheses were used as markers (kindly provided
by Dr Aletras).
Assay of MDAMB453 cell metastatic deposit formation
in the lung tissue
SCID mice were originally purchased from Jackson
Laboratory, bred and maintained under specific patho-
gen free conditions at the Experimental Animal Unit of
the Hellenic Pasteur Institute. All of the experiments
with animals were done in accordance with the guide-
lines approved by the Ethical Committee of the Hellenic
Pasteur Institute. The in vivo metastatic deposit forma-
tion assay, was performed as previously described
[31,17] Briefly, cultured MDAMB453 cells were pre-
incubated with DiI for 1 hour, washed twice with PBS,
trypsinized and made up to the cell density of 10
6/
300 μL in PBS in the absence or presence of 100 μg/ml
of an irrelevant antibody named of mAb BM88[27] or
100 μg/ml of mAb 4C5. Twenty 8- 10-week-old female
SCID mice were injected through the tail vein with
0.3 ml of the above cell preparations. The animals were
divided into two equal groups: the control group
injected with cells dialysed in PBS or the irrelevant anti-
body, mAb BM88 and the mAb 4C5 treated group. The
animals were euthanized 24 hours later and with the use
of a peristaltic pump connected to the left ventricle of
the heart, their lungs were completely washed from the
remaining blood, by pumpin g2 0 0m lo fs a l i n eb u f f e r .
This procedure ensures that all cancer cells which are
not attached, either on the inner surface of the blood
vessels or on the lung tissue, are removed. Finally the
lungs were perfused with 4% formalin solution and then
embedded in OCT solution in order to perform cryosec-
tions. Each lung was sectioned with the cryotome and
each section was counter stained with Dapi and visua-
lised with a confocal microscope. In ten randomly cho-
sen slides covering the whole of the lung tissue the
MDAMB453 cells were calculated. The same experiment
was performed twice with similar results.
Evaluation of tumor cell retention in the pulmonary
vessels
In the above mentioned lung sections the total number
of blood vessels was calculated and MDAMB453 stag-
nating cells were visualized and compared between the
control and the mAb 4C5 treated animals.
Statistical analysis
For the experimental groups that were statistically ana-
lyzed for differences, Student’s t test was used, in which
p < 0.05 was defined as statistically significant.
Additional material
Additional file 1: Additional figure showing that the antibody
against HSP90b does not recognize the HSP90a isoform.T h e
western blot analysis of human recombinant HSP90a and total cell
lysates (positive control) derived from MDAMB453 cell cultures using
anti-HSP90a (positive control) and anti-HSP90b antibodies.
Additional file 2: Additional figure legend. A file containing the
legend of the additional figure.
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